Search

Displaying results 1311 - 1320 of 1571 in total
  1. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various ...

  2. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the

    Categories: Complex Mixtures
  3. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability.

  4. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.

  5. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [L35310] Although the exact pathophysiology of glaucoma is still unknown, one of the main hallmarks of this disease is vascular dysregulation and abnormalities.

  6. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma … when compared to [crizotinib].

  7. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant. Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasti...

  8. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

  9. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    Concerta also provides a sustained 10-12 hour effect, allowing for once-daily dosing. … Within an aqueous environment, such as the stomach, the drug overcoat, which consists of 22% of the dose, dissolves within one hour, providing an initial immediate-release formulation of methylphenidate

  10. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.